Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 9/20 | 0.54 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245758 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TAS1R3TAS1R1BIRC2POLB | |
| SCHEMBL11316551 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TAS1R3TAS1R1BIRC2POLB | |
| SCHEMBL24178319 | 0.93 | BIRC2 (0.57) | ALDH1A1TAS1R3TAS1R1BIRC2POLB | |
| SCHEMBL5808683 | 0.84 | ALDH1A1 (0.60) | ALDH1A1TAS1R3TAS1R1BIRC2POLB | |
| SCHEMBL10795132 | 0.84 | ALDH1A1 (0.60) | ALDH1A1TAS1R3TAS1R1BIRC2POLB | |
| SCHEMBL5813379 | 0.84 | ALDH1A1 (0.60) | ALDH1A1TAS1R3TAS1R1BIRC2POLB | |
| SCHEMBL5813383 | 0.84 | ALDH1A1 (0.60) | ALDH1A1TAS1R3TAS1R1BIRC2POLB | |
| SCHEMBL5808681 | 0.84 | ALDH1A1 (0.60) | ALDH1A1TAS1R3TAS1R1BIRC2POLB | |
| SCHEMBL21488669 | 0.84 | ALDH1A1 (0.60) | ALDH1A1TAS1R3TAS1R1BIRC2POLB | |
| SCHEMBL15435453 | 0.84 | ALDH1A1 (0.60) | ALDH1A1TAS1R3TAS1R1BIRC2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511318-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2019-07-17 | — | — | EP | claimed |
| EP-3368508-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-09-05 | — | — | EP | claimed |
| US-20180243421-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-08-30 | — | — | US | claimed |
| WO-2017073797-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2017-05-04 | — | — | WO | claimed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | claimed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| US-4259441-A | Process for resolving D, L-leucine | ETHYL CORPORATION (US) | 1981-03-31 | — | — | US | claimed |
| US-20240208895-A1 | BRANCHED-CHAIN AMINO ACID DERIVATIVES TO TREAT DISEASE | Intrabio Ltd. (GB) | 2024-06-27 | — | — | US | disclosed |
| WO-2021038426-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-03-04 | — | — | WO | disclosed |
| EP-3511318-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2019-07-17 | — | — | EP | disclosed |
| EP-3368508-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-20180243421-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-08-30 | — | — | US | disclosed |
| WO-2017073797-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2017-05-04 | — | — | WO | disclosed |
| US-5329015-A | Catalysts for stereospecific reactions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-07-12 | — | — | US | disclosed |
| EP-0592552-A1 | CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES. | DU PONT (US) | 1994-04-20 | — | — | EP | disclosed |
| WO-1993001199-A1 | CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-01-21 | — | — | WO | disclosed |
| US-5171892-A | Chiral phospholanes via chiral 1,4-diol cyclic sulfates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-12-15 | — | — | US | disclosed |
| US-4670395-A | Enantioselective hydrolysis of N-acylamino acid esters using a combined enzyme system | THE STANDARD OIL COMPANY (US) | 1987-06-02 | — | — | US | disclosed |
| US-4259441-A | Process for resolving D, L-leucine | ETHYL CORPORATION (US) | 1981-03-31 | — | — | US | disclosed |
| US-RE29843-E | Substituted thiazoles and flavoring processes and products produced thereby | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243421-A1 | IMMUNOSTIMULATING AGENT | MYD88, IL2, IFNG | ALDH1A1 2303/4885TAS1R3 3987/4885TAS1R1 3730/4885 |
| US-20240208895-A1 | BRANCHED-CHAIN AMINO ACID DERIVATIVES TO TREAT DISEASE | CTSA, GBA1, GAA | ALDH1A1 2303/4885TAS1R3 921/4885TAS1R1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.